
QMS Medical Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- QMS Medical Allied Services aims for steady growth of 15-25% annually.
- Additional growth expected from expansion into hospital sectors and government business collaborations (e.g., Saarathi Healthcare and Chhattisgarh government TV screening programs).
- Online business, though new (approx. 145 days), shows promising outlook with plans to increase product portfolio from current ~40 to 100 products covering health and wellness.
- Shift from product sales to solutions ecosystem is improving operating margins.
- Plans to scale private brand sales significantly, targeting around ₹10 crores annually, leveraging B2B and online retail channels.
- Service models have better margins than product sales, expected to contribute more to revenue growth.
- Overall, QMS anticipates growth both from expanding product offerings and scaling service-driven patient programs across India.
See what QMS Medical management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript does not mention any current or planned fundraising through debt or equity.
- No statements or discussions about raising capital through funding rounds or debt instruments are present.
- The focus is on organic growth, acquisitions (like the 51% stake in Saarathi Healthcare), and business expansion.
- Strategic growth is driven by increasing product portfolio, expanding service offerings, and scaling operations rather than fundraising efforts.
- Investors are encouraged to connect for meetings, but no fundraising plans are disclosed in this call.
See what QMS Medical management said on order book — free account, 30 seconds.
Capex plans
Yes- QMS Medical Allied Services does not have its own manufacturing facilities; it relies entirely on third-party vendors trusted and quality-approved by IIT Mumbai.
- The company has recently acquired a 51% stake in Saarathi Healthcare Private Limited, marking a strategic expansion.
- They have acquired a government business model from the Chhattisgarh government related to TB patient services, expanding their patient service segment.
- There is a focus on expanding the product portfolio significantly—from around 38-40 products currently to aiming for 100 products within a year.
- Investment is directed towards service business growth, including equipment like diabetic retinopathy machines, Hb1C machines, and BMD machines (each costing approximately ₹8 lakh).
- The company is expanding its hospital billing and hospital segment operations.
- Online business expansion forms a part of future strategy, leveraging e-commerce platforms to reach wider markets.
Track QMS Medical — get its next earnings analysis in your feed
How does QMS Medical rank vs peers in Healthcare Equipment & Supplies?
Pro featureHow does QMS Medical rank in Healthcare Equipment & Supplies?
Compare QMS Medical against every Healthcare Equipment & Supplies company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What QMS Medical's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Fischer Medical (Q2 FY27)
For the quarter ended September 30, 2026, the Standalone revenue from operations was ₹27.62 Lakhs compared to ₹742.69 Lakhs in Q2 FY 2025, showing a…
- Mohini Health (Q2 FY27)
Revenue from operations for the half year ended 30th Sept 2026 is ₹11,043.00 lakhs, compared to ₹7,353.87 lakhs for the half year ended 30th Sept 2025, showing…
- Aprameya Enginee (Q2 FY27)
216.21 lakhs, up 97% year-on-year (YoY). Key results statement takeaways from Aprameya Engineering Ltd's Q2 FY27 results statement — and how it ranks against se
- OSEL Devices (Q2 FY27)
Revenue from operations for H1 FY27: ₹193.6 Cr, up 31.8% YoY from ₹146.9 Cr in H1 FY26 (Page 4, 20). Key investor presentation takeaways from OSEL Devices Ltd's